表紙
市場調査レポート

子宮頸癌:パイプライン分析

Cervical Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232853
出版日 ページ情報 英文 441 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
子宮頸癌:パイプライン分析 Cervical Cancer - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 441 Pages
概要

子宮頸癌は、ヒトパピローマウイルスが原因であるものが多く、初期における自覚症状はほとんどありません。症状は不正出血、性交時や閉経後、月経期間以外の出血または帯下、通常よりも長期または大量の月経出血などであり、治療には外科的手術、放射線治療、化学療法などの併用療法が用いられます。

当レポートでは、子宮頸癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

子宮頸癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • 3SBio Inc.
  • Admedus Ltd
  • Advaxis, Inc.
  • Advenchen Laboratories, LLC
  • AnGes MG, Inc.
  • Antigen Express, Inc.
  • Arbor Vita Corporation
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Azaya Therapeutics, Inc.
  • Blirt S.A.
  • Bristol-Myers Squibb Company
  • Cancer Research Technology Limited
  • Cellceutix Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Coherus BioSciences, Inc.
  • Critical Outcome Technologies Inc.
  • CZ BioMed Corp
  • DelMar Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • エーザイ
  • Eureka Therapeutics, Inc
  • EyeGene, Inc. 63
  • F. Hoffmann-La Roche Ltd.
  • Formune S.L.
  • Genexine, Inc.
  • Genmab A/S
  • Genor BioPharma Co., Ltd.
  • Genticel S.A.
  • GlaxoSmithKline Plc
  • Immunovaccine, Inc.
  • ISA Pharmaceuticals B.V.
  • Johnson & Johnson
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • LondonPharma Ltd
  • Mabion SA . 77
  • MedImmune, LLC
  • MEI Pharma, Inc.
  • Mundipharma International Ltd
  • Mycenax Biotech Inc.
  • Nanotherapeutics, Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Oncobiologics, Inc.
  • 小野薬品工業 .
  • Oryx GmbH & Co. KG
  • 大塚ホールディングス
  • PDS Biotechnology Corporation
  • Pfizer Inc.
  • Psicofarma S.A. de C.V.
  • Rexahn Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi
  • Savoy Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shantha Biotechnics Limited
  • Sirnaomics, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • 大鵬薬品工業
  • Theravectys SA
  • Tomegavax, Inc.
  • UbiVac, LLC
  • Vaccibody AS
  • VLPbio
  • Zeria Pharmaceutical Co., Ltd.
  • Zydus Cadila Healthcare Limited

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7994IDB

Summary

Global Markets Direct's, 'Cervical Cancer - Pipeline Review, H1 2016', provides an overview of the Cervical Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
  • The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Cervical Cancer Overview
  • Therapeutics Development
  • Cervical Cancer - Therapeutics under Development by Companies
  • Cervical Cancer - Therapeutics under Investigation by Universities/Institutes
  • Cervical Cancer - Pipeline Products Glance
  • Cervical Cancer - Products under Development by Companies
  • Cervical Cancer - Products under Investigation by Universities/Institutes
  • Cervical Cancer - Companies Involved in Therapeutics Development
  • Cervical Cancer - Therapeutics Assessment
  • Drug Profiles
  • Cervical Cancer - Recent Pipeline Updates
  • Cervical Cancer - Dormant Projects
  • Cervical Cancer - Discontinued Products
  • Cervical Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cervical Cancer, H1 2016
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Cervical Cancer - Pipeline by 3SBio Inc., H1 2016
  • Cervical Cancer - Pipeline by Admedus Ltd, H1 2016
  • Cervical Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Cervical Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Cervical Cancer - Pipeline by AnGes MG, Inc., H1 2016
  • Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2016
  • Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2016
  • Cervical Cancer - Pipeline by ArQule, Inc., H1 2016
  • Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Cervical Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Blirt S.A., H1 2016
  • Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2016
  • Cervical Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Cervical Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2016
  • Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
  • Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Cervical Cancer - Pipeline by EirGenix Inc., H1 2016
  • Cervical Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
  • Cervical Cancer - Pipeline by EyeGene, Inc., H1 2016
  • Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Cervical Cancer - Pipeline by Formune S.L., H1 2016
  • Cervical Cancer - Pipeline by Genexine, Inc., H1 2016
  • Cervical Cancer - Pipeline by Genmab A/S, H1 2016
  • Cervical Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Genticel S.A., H1 2016
  • Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Cervical Cancer - Pipeline by Immunovaccine, Inc., H1 2016
  • Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016
  • Cervical Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2016
  • Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2016
  • Cervical Cancer - Pipeline by Mabion SA, H1 2016
  • Cervical Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2016
  • Cervical Cancer - Pipeline by Mundipharma International Ltd, H1 2016
  • Cervical Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
  • Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2016
  • Cervical Cancer - Pipeline by Novartis AG, H1 2016
  • Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016
  • Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016
  • Cervical Cancer - Pipeline by Pfizer Inc., H1 2016
  • Cervical Cancer - Pipeline by Psicofarma S.A. de C.V., H1 2016
  • Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
  • Cervical Cancer - Pipeline by Samyang Holdings Corporation, H1 2016
  • Cervical Cancer - Pipeline by Sanofi, H1 2016
  • Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • Cervical Cancer - Pipeline by Seattle Genetics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2016
  • Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2016
  • Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Theravectys SA, H1 2016
  • Cervical Cancer - Pipeline by Tomegavax, Inc., H1 2016
  • Cervical Cancer - Pipeline by UbiVac, LLC, H1 2016
  • Cervical Cancer - Pipeline by Vaccibody AS, H1 2016
  • Cervical Cancer - Pipeline by VLPbio, H1 2016
  • Cervical Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H1 2016
  • Cervical Cancer - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Cervical Cancer - Dormant Projects, H1 2016
  • Cervical Cancer - Dormant Projects (Contd..1), H1 2016
  • Cervical Cancer - Dormant Projects (Contd..2), H1 2016
  • Cervical Cancer - Dormant Projects (Contd..3), H1 2016
  • Cervical Cancer - Dormant Projects (Contd..4), H1 2016
  • Cervical Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Cervical Cancer, H1 2016
  • Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top